Cargando…

The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia

Aberrant Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling is implicated in the pathogenesis of acute myeloid leukemia (AML), a highly heterogeneous hematopoietic malignancy. The management of AML is complex and despite impressive efforts into better understanding it...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moser, Bernhard, Edtmayer, Sophie, Witalisz-Siepracka, Agnieszka, Stoiber, Dagmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392322/ https://www.ncbi.nlm.nih.gov/pubmed/34440253 http://dx.doi.org/10.3390/biomedicines9081051

Ejemplares similares

PB1805: BREAKING A PARADIGM: LOSS OF STAT3 INCREASES INVASION IN MLL-AF9-DRIVEN ACUTE MYELOID LEUKEMIA
por: Zdársky, Bernhard, et al.
Publicado: (2023)

PB1783: UNRAVELING THE TUMOR SUPPRESSIVE ROLE OF STAT3B IN ACUTE MYELOID LEUKEMIA
por: Edtmayer, Sophie, et al.
Publicado: (2023)

PB1831: THE BALANCE BETWEEN STAT3 ISOFORMS AS ESSENTIAL FEATURE IN ACUTE MYELOID LEUKEMIA
por: Weiss, Stefanie, et al.
Publicado: (2023)

The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance
por: Witalisz-Siepracka, Agnieszka, et al.
Publicado: (2022)

Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?
por: Klein, Klara, et al.
Publicado: (2021)

CDK8-Novel Therapeutic Opportunities
por: Menzl, Ingeborg, et al.
Publicado: (2019)

STAT5B(N642H) drives transformation of NKT cells: a novel mouse model for CD56(+) T-LGL leukemia
por: Klein, Klara, et al.
Publicado: (2019)

Pharmacologic inhibition of STAT5 in acute myeloid leukemia
por: Wingelhofer, Bettina, et al.
Publicado: (2018)

Myeloid Leukemia of Down Syndrome
por: Kosmidou, Aikaterini, et al.
Publicado: (2023)

P1273: INVESTIGATING THE ONCOGENIC POTENTIAL OF STAT5BN642H IN NK CELLS
por: Klein, K., et al.
Publicado: (2022)

Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core
por: Grimm, Juliane, et al.
Publicado: (2022)

T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo
por: Klein, Klara, et al.
Publicado: (2021)

STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity
por: Meissl, Katrin, et al.
Publicado: (2020)

In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity
por: Prchal-Murphy, Michaela, et al.
Publicado: (2015)

Loss of JAK1 Drives Innate Immune Deficiency
por: Witalisz-Siepracka, Agnieszka, et al.
Publicado: (2019)

Heterogeneous sensitivity of human Acute Myeloid Leukemia to ß-catenin down-modulation
por: Gandillet, Arnaud, et al.
Publicado: (2011)

Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia
por: Jiang, Xi, et al.
Publicado: (2017)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Triple-negative breast cancer cells rely on kinase-independent functions of CDK8 to evade NK-cell-mediated tumor surveillance
por: Knab, Vanessa Maria, et al.
Publicado: (2021)

Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness
por: Grandits, Alexander Michael, et al.
Publicado: (2021)

Acute Myeloid Leukemia: Is It T Time?
por: Khoud, Meriem Ben, et al.
Publicado: (2021)

Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia
por: Jiang, Xi, et al.
Publicado: (2018)

Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia
por: Mencalha, André L, et al.
Publicado: (2014)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia
por: Wilde, Lindsay, et al.
Publicado: (2020)

Loss of NKG2D in murine NK cells leads to increased perforin production upon long‐term stimulation with IL‐2
por: Prinz, Daniela, et al.
Publicado: (2020)

Classification of acute myeloid leukemia
por: Hwang, Sang Mee
Publicado: (2020)

Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway
por: Tan, Jinshui, et al.
Publicado: (2023)

Pharmacological inhibiting STAT5 for the treatment of FLT3‐ITD‐positive acute myeloid leukemia with triciribine phosphate monohydrate
por: Wu, Hong, et al.
Publicado: (2023)

Cell-selective oligonucleotide STAT3 inhibitor for immunotherapy of human acute myeloid leukemia
por: Zhang, Qifang, et al.
Publicado: (2015)

Identification and Validation of STAT6 as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia
por: Liu, Wei, et al.
Publicado: (2020)

Emerging Immunotherapy for Acute Myeloid Leukemia
por: Tabata, Rikako, et al.
Publicado: (2021)

Chromosomal Instability in Acute Myeloid Leukemia
por: de Oliveira Lisboa, Mateus, et al.
Publicado: (2021)

RSK Isoforms in Acute Myeloid Leukemia
por: Youn, Minyoung, et al.
Publicado: (2021)

Circular RNAs in acute myeloid leukemia
por: Singh, Vijendra, et al.
Publicado: (2021)

Tipifarnib in the treatment of acute myeloid leukemia
por: Thomas, Xavier, et al.
Publicado: (2007)

Differentiation Therapy of Acute Myeloid Leukemia
por: Gocek, Elzbieta, et al.
Publicado: (2011)

Comparative proteomics in acute myeloid leukemia
por: Luczak, Magdalena, et al.
Publicado: (2012)

Precision therapy for acute myeloid leukemia
por: Yang, Xue, et al.
Publicado: (2018)

Novel Agents for Acute Myeloid Leukemia
por: Luppi, Mario, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jo05c70o28dl7hh0qd7p7328gj